China's Ministry Of Health To Expand Corruption Probe In Pharma Sector
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Investors in China-based pharmaceutical firms have been so rattled by a widening government probe into potentially improper payments to regulators and doctors, and by the review of drug price levels for possible state-mandated cuts, that they have begun selling off equity stakes in those firms, according to a prominent analyst who closely follows China's healthcare sector from Merrill Lynch's office in Hong Kong